The USA Food and Drug Administration approved pembrolizumab for chemorefractory patients with programmed death ligand 1 (PD-L1)-positive AGC and mismatch repair deficiency or high tumour mutational burden (TMB) (≥10 mutations/Mb) [4–6]. Here, CD274 is linked to neoplasm.